CoChat

Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis

Kumar, C. · 2003 · Current Drug Targets

The DOI matches its Crossref record.

Abstract

The integrin receptor alphavbeta3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that alphavbeta3 is a critical target downstream from perhaps all angiogcnic factors. Proof-of-principle that alphavbeta3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the alphavbeta3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the alphavbeta3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting.

Overview

Integrity signals

Registry

Crossref · 10.2174/1389450033346830

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Items 201–283 of 283

Metadata

Authors
Kumar, C.
Corresponding author
Kumar, C.
Venue
Current Drug Targets
Published
2003-02-01
Volume
4
Issue
2
Pages
123-131
ISSN
1389-4501 (ISSN-L)
OpenAlex
W147592962
Cited by
280
References
0
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 4 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 20 · 2012: 20
FWCI
10.63
Type
journal article
Language
en
Open access
closed
Locations
  • Current Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
integrin αvβ3, tumor angiogenesis, angiogenesis inhibitors, monoclonal antibodies, small molecule antagonists, angiostatin, endostatin, tumstatin, tumor growth, metastasis, bone metastasis, osteoclast resorption, rheumatoid arthritis, osteoporosis, therapeutic target
MeSH terms
Animals, Humans, Neoplasms, Neovascularization, Pathologic, Drug Delivery Systems, Angiogenesis Inhibitors, Integrin alphaVbeta3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.